Not to be confused with 3-MeO-PCP.

Summary sheet: 4-MeO-PCP

{{#arraydefine: InhaledDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: InhaledDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: SmokedDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: SmokedDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: OralDosage | Threshold;Oral threshold dose::25Oral dose units::mg, Light;Oral min light dose::75 - Oral max light dose::100 mg, Common;Oral min common dose::100 - Oral max common dose::170 mg, Strong;Oral min strong dose::170 - Oral max strong dose::250 mg, Heavy;Oral heavy dose::250 mg + }} {{#arraydefine: OralDuration | Total;Oral min total time::12 - Oral max total time::20Oral total time units::hours, Onset;Oral min onset time::45 - Oral max onset time::120Oral onset time units::minutes, Come up;Oral min comeup time::1 - Oral max comeup time::2Oral comeup time units::hours, Peak;Oral min peak time::3 - Oral max peak time::7Oral peak time units::hours, Offset;Oral min offset time::6 - Oral max offset time::10Oral offset time units::hours, After effects;6+ hours }} {{#arraydefine: SublingualDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: SublingualDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: BuccalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: BuccalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: InsufflatedDosage | Threshold;Insufflated threshold dose::15Insufflated dose units::mg, Light;Insufflated min light dose::30 - Insufflated max light dose::75 mg, Common;Insufflated min common dose::75 - Insufflated max common dose::150 mg, Strong;Insufflated heavy dose::150mg +, Heavy; }} {{#arraydefine: InsufflatedDuration | Total;Insufflated min total time::12 - Insufflated max total time::18Insufflated total time units::hours, Onset;Insufflated min onset time::5 - Insufflated max onset time::15Insufflated onset time units::minutes, Come up;Insufflated min comeup time::15 - Insufflated max comeup time::30Insufflated comeup time units::minutes, Peak;Insufflated min peak time::3 - Insufflated max peak time::6Insufflated peak time units::hours, Offset;Insufflated min offset time::3Insufflated offset time units::hours, After effects;Insufflated min afterglow time::3Insufflated afterglow time units::hours }} {{#arraydefine: RectalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: RectalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: TransdermalDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: TransdermalDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: SubcutaneousDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: SubcutaneousDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: IntramuscularDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: IntramuscularDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: IntravenousDosage | Threshold;, Light;, Common;, Strong;, Heavy; }} {{#arraydefine: IntravenousDuration | Total;, Onset;, Come up;, Peak;, Offset;, After effects; }} {{#arraydefine: uncertaininteractions | {{#ask:4-MeO-PCP |?UncertainInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arraydefine: unsafeinteractions | {{#ask:4-MeO-PCP |?UnsafeInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arraydefine: dangerousinteractions | {{#ask:4-MeO-PCP |?DangerousInteraction |headers=hide |format=list |mainlabel=- |link=none }} }} {{#arrayprint:uncertaininteractions||@@@@| }} {{#arrayprint:unsafeinteractions||@@@@| }} {{#arrayprint:dangerousinteractions||@@@@| }}

4-MeO-PCP
Chemical Nomenclature
Common names	common name::4-MeO-PCP, common name::Methoxydine
Substitutive name	4-Methoxyphencyclidine
Systematic name	1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine
Class Membership
Psychoactive class	psychoactive class::Dissociative
Chemical class	chemical class::Arylcyclohexylamine
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. {{#arrayunique: OralDosage}} {{#loop: i | 0 | {{#arraysize: OralDosage}} | {{#arraydefine: val | {{#arrayindex: OralDosage | {{#var: i}} }} | ; }} }} {{#arrayunique: OralDuration}} {{#loop: i | 0 | {{#arraysize: OralDuration}} | {{#arraydefine: val | {{#arrayindex: OralDuration | {{#var: i}} }} | ; }} }} ⇣ Oral Dosage [[Dosage_classification#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} Duration [[Duration#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} {{#arrayunique: InsufflatedDosage}} {{#loop: i | 0 | {{#arraysize: InsufflatedDosage}} | {{#arraydefine: val | {{#arrayindex: InsufflatedDosage | {{#var: i}} }} | ; }} }} {{#arrayunique: InsufflatedDuration}} {{#loop: i | 0 | {{#arraysize: InsufflatedDuration}} | {{#arraydefine: val | {{#arrayindex: InsufflatedDuration | {{#var: i}} }} | ; }} }} ⇣ Insufflated Dosage [[Dosage_classification#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} Duration [[Duration#{{#arrayindex: val | 0 }}|{{#arrayindex: val | 0 }}]] {{#arrayindex: val | 1 }} DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions
@@@@
@@@@
@@@@

4-Methoxyphencyclidine (abbreviated 4-MeO-PCP) is a synthetic Psychoactive class::dissociative of the Chemical class::arylcyclohexylamine class which produces hallucinogenic and anesthetic effects.

The synthesis of 4-MeO-PCP was first reported in 1965 by the Parke-Davis medicinal chemist Victor Maddox. A 1999 review published by a chemist using the pseudonym John Q. Beagle suggested the potency of 4-MeO-PCP in man was reduced relative to PCP. Two years later, Beagle published a detailed description of the synthesis and qualitative effects of 4-MeO-PCP which he said possessed 70% of the potency of PCP.

4-MeO-PCP was the first arylcyclohexylamine research chemical to be sold online. It was introduced in late 2008 by a company trading under the name CBAY and was followed by several related compounds such as 3-MeO-PCP and Methoxetamine (MXE).

Chemistry

4-MeO-PCP, or 4-Methoxyphencyclidine, is a synthetic dissociative of the arylcyclohexylamine class. 4-MeO-PCP contains cyclohexane, a six member saturated ring, bonded to two additional rings at R₁. One of these rings is a piperidine ring (a nitrogenous six member ring) bonded at its nitrogen group. The other ring is an aromatic phenyl ring substituted at R₄ with a methoxy group. 4-MeO-PCP is a PCP derivative, and structurally analogous to 3-MeO-PCP.

Pharmacology

Further information: NMDA receptor antagonist

4-MeO-PCP acts as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “k-hole.”

4-MeO-PCP has lower affinity for the NMDA receptor than PCP, but higher affinity than ketamine. It is orally active in a dosage range similar to ketamine with some users requiring doses in excess of 100mg for desired effects. Users have reported substantial differences in active dose; these discrepancies can be partially explained by the presence of unreacted PCC and other impurities in samples sold on the grey market. Though 4-MeO-PCP has been suggested to possess dopaminergic activity, it is a relatively selective ligand for the NMDA receptor without appreciable affinity for the dopamine transporter.

Subjective effects

File:Metacogghjgjvghnition.png

This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

{{

 #fornumargs: number
 | column
 | 

{{#var: column}} }}

Experience reports

There are currently {{#ask: | format=count}} experience reports describing the effects of this substance in our experience index. You can also submit your own experience report using the same link. {{#ask: |format=ul|Columns=1}} Additional experience reports can be found here:

• - |Lotus I Lily }}|Mushrooms - |Mushrooms }}|Pharms - |Pharms }}|Products - |Products }}|Smarts - |Smarts }}| |_}}|-|}}.shtml Erowid Experience Vaults: 4-MeO-PCP Reports

Potentially dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

• Stimulants - Both stimulants and dissociatives carry the risk of adverse psychological reactions like anxiety, mania, delusions and psychosis and these risks are exacerbated when the two substances are combined.
• Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.

Toxicity and harm potential

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens

The toxicity and long-term health effects of recreational 4-MeO-PCP use do not seem to have been studied in any scientific context and the Toxicity::exact toxic dosage is unknown. This is because 4-MeO-PCP has very little history of human usage. Anecdotal evidence from people who have tried 4-MeO-PCP within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other NMDA receptor antagonists, the chronic use of 4-MeO-PCP can be considered Addiction potential::moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 4-MeO-PCP Time to full tolerance::develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about Time to half tolerance::3 - 7 days for the tolerance to be reduced to half and Time to zero tolerance::1 - 2 weeks to be back at baseline (in the absence of further consumption). 4-MeO-PCP presents cross-tolerance with [[Cross-tolerance::all dissociatives]], meaning that after the consumption of 4-MeO-PCP all dissociatives will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

• Stimulants - Both stimulants and dissociatives carry the risk of adverse psychological reactions like anxiety, mania, delusions and psychosis and these risks are exacerbated when the two substances are combined.
• Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.

Urinary tract effects

In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, 4-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine but to a lesser extent. This is because 4-MeO-PCP is a little more potent than ketamine, meaning that less of the drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:

• Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
• Urinary urgency - This can be described as a sudden, compelling need to urinate.
• Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
• Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
• Hematuria - Hematuria is visible blood in the urine.
• Incontinence - This is the leakage of urine.

All of these, however, can easily be avoided by simply not using 4-MeO-PCP on a daily or even weekly basis and manually limiting one's usage of the substance.

Legal status

File:Handcuffs-300px.png

This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

• Germany: 4-MeO-PCP is a controlled substance under the NpSG since 27th September 2021.
• Sweden - Sweden's public health agency suggested classifying 4-MeO-PCP as a hazardous substance on November 10, 2014.
• Switzerland: 4-MeO-PCP is a controlled substance specifically named under Verzeichnis E.
• Turkey: 4-MeO-PCP is a classed as drug and is illegal to possess, produce, supply, or import.
• United Kingdom - 4-MeO-PCP is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.

See also

• Responsible use
• Research chemical
• Dissociatives
• Arylcyclohexylamines
• 3-MeO-PCP
• PCP

External links

• 4-MeO-PCP (Wikipedia)
• 4-MeO-PCP (Erowid Vault)
• 4-MeO-PCP (Isomer Design)
• 4-MeO-PCP (Bluelight)
• Interview with a Ketamine Chemist (VICE)

Literature

• Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620

References

{{#set:Featured=true}}